CA2831713C - Derives d'acide hydroxybisphosphonique bifonctionnels et leur utilisation dans la vectorisation de molecules d'interet therapeutique ou diagnostique - Google Patents

Derives d'acide hydroxybisphosphonique bifonctionnels et leur utilisation dans la vectorisation de molecules d'interet therapeutique ou diagnostique Download PDF

Info

Publication number
CA2831713C
CA2831713C CA2831713A CA2831713A CA2831713C CA 2831713 C CA2831713 C CA 2831713C CA 2831713 A CA2831713 A CA 2831713A CA 2831713 A CA2831713 A CA 2831713A CA 2831713 C CA2831713 C CA 2831713C
Authority
CA
Canada
Prior art keywords
compound
group
divalent
bisphosphonic acid
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2831713A
Other languages
English (en)
French (fr)
Other versions
CA2831713A1 (fr
Inventor
Maxim Egorov
Jean-Yves GOUJON
Ronan LE BOT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlanthera SAS
Original Assignee
Atlanthera SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlanthera SAS filed Critical Atlanthera SAS
Publication of CA2831713A1 publication Critical patent/CA2831713A1/fr
Application granted granted Critical
Publication of CA2831713C publication Critical patent/CA2831713C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3869—Polyphosphonic acids containing carboxylic acid or carboxylic acid derivative substituents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2831713A 2011-03-28 2012-03-28 Derives d'acide hydroxybisphosphonique bifonctionnels et leur utilisation dans la vectorisation de molecules d'interet therapeutique ou diagnostique Active CA2831713C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1152546A FR2973378B1 (fr) 2011-03-28 2011-03-28 Derives d'acide hydroxybisphosphonique bifonctionnels
FR1152546 2011-03-28
PCT/EP2012/055569 WO2012130911A1 (fr) 2011-03-28 2012-03-28 Derives d'acide hydroxybisphosphonique bifonctionnels

Publications (2)

Publication Number Publication Date
CA2831713A1 CA2831713A1 (fr) 2012-10-04
CA2831713C true CA2831713C (fr) 2020-09-15

Family

ID=45926557

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2831713A Active CA2831713C (fr) 2011-03-28 2012-03-28 Derives d'acide hydroxybisphosphonique bifonctionnels et leur utilisation dans la vectorisation de molecules d'interet therapeutique ou diagnostique

Country Status (7)

Country Link
US (1) US9173946B2 (https=)
EP (1) EP2691402B1 (https=)
JP (1) JP6026499B2 (https=)
CA (1) CA2831713C (https=)
ES (1) ES2743276T3 (https=)
FR (1) FR2973378B1 (https=)
WO (1) WO2012130911A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028762B1 (fr) 2014-11-20 2017-01-06 Atlanthera Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
JP6209643B2 (ja) * 2015-04-20 2017-10-04 タイワン ホパックス ケミカルズ マニュファクチャリング カンパニー リミテッドＴａｉｗａｎ Ｈｏｐａｘ Ｃｈｅｍｓ．Ｍｆｇ．Ｃｏ．，Ｌｔｄ 親骨性薬剤
WO2020163637A1 (en) * 2019-02-06 2020-08-13 Oregon Health & Science University Bisphosphonate-linked compounds
CN114585316A (zh) * 2019-07-24 2022-06-03 布莱阿姆青年大学 骨结合化合物
US11679099B2 (en) * 2020-05-13 2023-06-20 Seoul National University R&Db Foundation Use of HIF-2α inhibitors for treating chondrosarcoma, or preventing recurrence and metastasis thereof
FR3122427B1 (fr) 2021-04-30 2025-03-07 Atlanthera Derives hydroxybisphosphoniques de meloxicam pour traitement des maladies inflammatoires osteoarticulaires
CN118475661A (zh) * 2021-12-10 2024-08-09 Ppg工业俄亥俄公司 肼基甲酸酯官能化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2296080A1 (fr) 1974-12-26 1976-07-23 Yoshida Kogyo Kk Bloc fenetre exterieur pourvu d'un appui de chassis fixe perfectionne
US4830847A (en) * 1985-06-28 1989-05-16 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
PH26923A (en) * 1989-03-08 1992-12-03 Ciba Geigy N-substituted amino alkanediphosphonic acids
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
WO2004089356A2 (en) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals Inc. Targeted bone marrow protection agents
US8404664B2 (en) * 2005-08-11 2013-03-26 Targanta Therapeutics, Inc. Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections
US8133311B2 (en) * 2007-04-30 2012-03-13 Cabot Corporation Pigment dipsersions comprising functionalized non-polymeric dispersants
FR2926080B1 (fr) * 2008-01-03 2010-04-02 Univ Nantes Procede de synthese de derives d'acide hydroxy-bisphosphonique
FR2926081B1 (fr) 2008-01-03 2010-02-19 Univ Nantes Derives d'acide hydroxy-bisphosphonique comme vecteur ciblant le tissu osseux
EP2289558A1 (en) * 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs

Also Published As

Publication number Publication date
WO2012130911A1 (fr) 2012-10-04
EP2691402B1 (fr) 2019-05-08
EP2691402A1 (fr) 2014-02-05
US20140086843A1 (en) 2014-03-27
ES2743276T3 (es) 2020-02-18
JP6026499B2 (ja) 2016-11-16
FR2973378B1 (fr) 2013-10-04
CA2831713A1 (fr) 2012-10-04
FR2973378A1 (fr) 2012-10-05
US9173946B2 (en) 2015-11-03
JP2014514288A (ja) 2014-06-19

Similar Documents

Publication Publication Date Title
CA2831713C (fr) Derives d'acide hydroxybisphosphonique bifonctionnels et leur utilisation dans la vectorisation de molecules d'interet therapeutique ou diagnostique
CA2711141C (fr) Derives d'acide hydroxy-bisphosphonique comme vecteur ciblant le tissu osseux
CA2945404A1 (en) Bone-selective osteogenic oxysterol bisphosphonate analogs
KR20110013411A (ko) (ｆ-19)-표지된 ｌ-글루탐산 및 ｌ-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법
JP5819523B2 (ja) カンプトテシン誘導体とその製造方法、医薬組成物とその用途
CN117157281B (zh) 1,2,4,5-四噁烷化合物的靶向递送及其用途
CN104211700B (zh) 咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用
JP2004010582A (ja) カルバ環状ホスファチジン酸誘導体
CN101220037B (zh) 10-位取代高喜树碱类化合物及其用途
WO2007145455A1 (en) Water soluble micelle-forming and biodegradable cyclotriphosphazene-taxol conjugate anticancer agent and preparation method thereof
AU2011222551B2 (en) Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
KR102322956B1 (ko) 신규 보르테조밉 전구약물 및 이의 용도
FR2725449A1 (fr) Derives de polyazacycloalcanes, leurs complexes metalliques et produits pharmaceutiques incorporant ces complexes
EP4458412A1 (en) Novel phosphoantigen prodrug compound and use thereof
FR3028762A1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
KR100603024B1 (ko) 온도 감응성을 갖는 포스파젠 삼량체-5-플루오로우라실복합체 및 그 제조 방법
CN116731305A (zh) 一种抗肿瘤大环内酯聚合物及其制备方法和应用
CN106146612A (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
ITMI990811A1 (it) Composti dimerici di rutenio utili quali agenti antimetastatici ed antineoplastici
DE102015201148A1 (de) Neuartige Phenylphosphate und deren Verwendung als Arzneimittel

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170328

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251014

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260126